Skip to content

ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03822988
Acronym
PADAONCODERM
Enrollment
150
Registered
2019-01-30
Start date
2019-01-21
Completion date
2019-06-20
Last updated
2019-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advance Directives, Melanoma, Metastatic Basal Cell Carcinoma, Oncology, Skin Cancer, Skin Lymphoma, Skin Squamous Cell Carcinoma

Keywords

advance directives, Advance care planning, Patient's informed, treatment preferences, skin cancer, dermatology

Brief summary

The law about advance directives is evolving but, in France, few people write it. Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic. Seconds endpoints are : For patients against or not planning to write it, understand their reasons Estimate the proportion of patients requesting information and understand how they would like to receive it. Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.

Interventions

OTHERno intervention, only complete a survey

we will ask patients to answer to a survey

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\> 18 ya With one of the diagnoses below: * Melanoma * Skin lymphoma * Meckel Carcinoma * localy advanced or metastatic Basal cell carcinoma or squamous cell carcinoma

Exclusion criteria

Patients not in possession of all of its cognitive abilities Patients who can't read patients who don't speak french

Design outcomes

Primary

MeasureTime frameDescription
Writing by the patient of its advance directiveswhen the patient complete the surveyWriting by the patient of his advance directves and, if not writing, positioning of the patient (rather favorable or rather unfavorable) as to the writing of his advance directives.

Secondary

MeasureTime frameDescription
Patient wishing to be more informed about the adavance directives during its management and, if so, by what means.when the patient complete the survey
reason for not writing advance directiveswhen the patient complete the surveyIn patients who have not written their advance directives: reason for not writing the advance directives.

Countries

France

Contacts

Primary ContactAnne-Claire BURSZTEJN
ac-bursztejn@chru-nancy.fr0383157146

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026